ES2560807T3 - Nuevos reactivos y procedimiento de conjugación de moléculas biológicas - Google Patents

Nuevos reactivos y procedimiento de conjugación de moléculas biológicas Download PDF

Info

Publication number
ES2560807T3
ES2560807T3 ES11171786.4T ES11171786T ES2560807T3 ES 2560807 T3 ES2560807 T3 ES 2560807T3 ES 11171786 T ES11171786 T ES 11171786T ES 2560807 T3 ES2560807 T3 ES 2560807T3
Authority
ES
Spain
Prior art keywords
peg
reagent
kda
solution
pegylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11171786.4T
Other languages
English (en)
Spanish (es)
Inventor
Anthony Godwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0813339A external-priority patent/GB0813339D0/en
Priority claimed from GB0905762A external-priority patent/GB0905762D0/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Application granted granted Critical
Publication of ES2560807T3 publication Critical patent/ES2560807T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES11171786.4T 2008-07-21 2009-07-17 Nuevos reactivos y procedimiento de conjugación de moléculas biológicas Active ES2560807T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0813339 2008-07-21
GB0813339A GB0813339D0 (en) 2008-07-21 2008-07-21 Novel reagents and method for conjugating biological molecules
GB0905762 2009-04-02
GB0905762A GB0905762D0 (en) 2009-04-02 2009-04-02 Novel reagents and method for conjugating biological molecules

Publications (1)

Publication Number Publication Date
ES2560807T3 true ES2560807T3 (es) 2016-02-22

Family

ID=41226122

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09784718.0T Active ES2536882T3 (es) 2008-07-21 2009-07-17 Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
ES11171786.4T Active ES2560807T3 (es) 2008-07-21 2009-07-17 Nuevos reactivos y procedimiento de conjugación de moléculas biológicas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09784718.0T Active ES2536882T3 (es) 2008-07-21 2009-07-17 Nuevos reactivos y procedimiento de conjugación de moléculas biológicas

Country Status (10)

Country Link
US (4) US8969626B2 (OSRAM)
EP (2) EP2374481B1 (OSRAM)
JP (2) JP5622117B2 (OSRAM)
KR (1) KR101763559B1 (OSRAM)
CN (1) CN102099058B (OSRAM)
AU (1) AU2009275358C1 (OSRAM)
DK (2) DK2374481T3 (OSRAM)
ES (2) ES2536882T3 (OSRAM)
PL (1) PL2326349T3 (OSRAM)
WO (1) WO2010010324A1 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
CN102099058B (zh) * 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
CA2811869A1 (en) * 2010-09-21 2012-03-29 Cristal Delivery B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
AU2012262428C1 (en) * 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
JP5841768B2 (ja) * 2011-08-05 2016-01-13 花王株式会社 脂肪蓄積抑制剤
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
KR102178606B1 (ko) 2013-03-15 2020-11-13 자임워크스 인코포레이티드 세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법
EA038512B1 (ru) 2013-03-15 2021-09-08 Регенерон Фармасьютикалз, Инк. Конъюгаты майтанзиноидов и их терапевтическое применение
CA2921412C (en) 2013-08-26 2024-05-28 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
WO2016160615A1 (en) 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
CA2987641A1 (en) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TW201811376A (zh) 2016-07-01 2018-04-01 英商葛蘭素史密斯克藍智慧財產權有限公司 抗體-藥物結合物及使用其之治療方法
RS63660B1 (sr) 2016-09-23 2022-11-30 Regeneron Pharma Anti-muc16 (mucin 16) antitela
MA46417A (fr) 2016-09-23 2019-07-31 Regeneron Pharma Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
MY199937A (en) 2016-11-08 2023-11-29 Regeneron Pharma Steroids and protein-conjugates thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
US12070506B2 (en) 2018-01-08 2024-08-27 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
EP3788075A1 (en) 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
MY206284A (en) 2018-05-17 2024-12-06 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
SG11202106658XA (en) 2018-12-21 2021-07-29 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof
JP2022523360A (ja) 2019-02-21 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
MX2022010599A (es) 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
KR20230004651A (ko) 2020-04-16 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 딜스-알더 접합 방법
BR112023000489A2 (pt) 2020-07-13 2023-03-28 Regeneron Pharma Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
US12280124B2 (en) 2020-09-14 2025-04-22 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof
IL301702A (en) 2020-10-22 2023-05-01 Regeneron Pharma Anti-FGFR2 antibodies and methods of using them
CN113461929B (zh) * 2021-07-13 2023-04-21 浙江倍合德制药有限公司 一种tpgs系列产品的精制提纯方法
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
CN119072335A (zh) 2022-03-11 2024-12-03 瑞泽恩制药公司 包含glp1肽模拟物的抗glp1r抗体-药物缀合物及其用途
CN120239705A (zh) 2022-07-21 2025-07-01 萤火虫生物股份有限公司 糖皮质激素受体激动剂和其缀合物
KR20250133813A (ko) 2022-12-21 2025-09-08 리제너론 파마슈티칼스 인코포레이티드 Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
US20250171516A1 (en) 2023-11-03 2025-05-29 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147443A (en) * 1874-02-10 Improvement in lamp-extinguishers
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
GB9713979D0 (en) 1997-07-03 1997-09-10 Univ Nottingham Method for attaching peg to macromolecules
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US6828412B1 (en) 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
JP4883515B2 (ja) 1999-09-08 2012-02-22 ポリセリックス リミテッド 均一分子量ポリマー
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
JP4009721B2 (ja) * 2003-05-23 2007-11-21 独立行政法人産業技術総合研究所 イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP1828244A2 (en) 2004-12-22 2007-09-05 Kuros Biosurgery AG Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
CN102099058B (zh) 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
WO2010100430A1 (en) * 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides

Also Published As

Publication number Publication date
CN102099058B (zh) 2014-10-22
CN102099058A (zh) 2011-06-15
JP2011252167A (ja) 2011-12-15
DK2326349T3 (en) 2015-05-26
AU2009275358B2 (en) 2015-05-28
US9896412B2 (en) 2018-02-20
KR101763559B1 (ko) 2017-08-14
PL2326349T3 (pl) 2015-08-31
EP2374481B1 (en) 2015-11-04
EP2374481A3 (en) 2012-06-13
US20110262994A1 (en) 2011-10-27
US20140081047A1 (en) 2014-03-20
EP2326349B1 (en) 2015-02-25
JP5626655B2 (ja) 2014-11-19
ES2536882T3 (es) 2015-05-29
US20110136723A1 (en) 2011-06-09
WO2010010324A1 (en) 2010-01-28
AU2009275358C1 (en) 2015-09-24
KR20110053430A (ko) 2011-05-23
EP2326349A1 (en) 2011-06-01
JP5622117B2 (ja) 2014-11-12
US20150148544A1 (en) 2015-05-28
US8618333B2 (en) 2013-12-31
US8969626B2 (en) 2015-03-03
DK2374481T3 (en) 2016-02-01
JP2011528706A (ja) 2011-11-24
EP2374481A2 (en) 2011-10-12
AU2009275358A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
ES2560807T3 (es) Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
CN104755106B (zh) 药物‑蛋白质缀合物
Vega et al. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly (L-glutamic acid) through a polyethylene glycol spacer
JP2013501764A (ja) 機能的分子の可逆的共有結合
KR20110025731A (ko) 에리트로포이에틴 모방 펩티드 유도체 및 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이의 용도
Ghetie et al. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers
Hudecz et al. Synthesis, conformation, biodistribution and in vitro cytotoxicity of daunomycin-branched polypeptide conjugates
US20250162975A1 (en) Compositions and methods for protein labeling, modification, analysis, and targeted delivery
CN115154419B (zh) 一种纳米胶束前体和纳米胶束，其制备方法及应用
FI104409B (fi) Kelaatinmuodostajia ja niitä sisältäviä, diagnostiikassa käytettäviä komplekseja
JP7252333B2 (ja) 酸法による抗体薬物複合体中間体の調製方法及びその応用
US8222449B2 (en) Metal oxide-chelating ligands
JPH02288891A (ja) 糖受容体に特異な低分子量合成キヤリヤ、それを含む共役物およびその製造法
BR112021008753A2 (pt) processo otimizado para conjugado dimérico de peptídio-fosfolipídio
CA3076714A1 (en) Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof